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ABSTRACT
Objective: The study was conducted with an objective to achieve a potential sustained release oral drug delivery system of an antihypertensive drug, 
perindopril which is a angiotensin converting enzyme inhibitor having half-life of 2 hrs. Perindopril is water-soluble drug, so we can control or delay 
the release rate of drug using release retarding polymers. This may also decrease the toxic side effects by preventing the high initial concentration in 
the blood.
Methods: Microcapsules were prepared by solvent evaporation technique using Eudragit L100 and ethyl cellulose as a retarding agent to control 
the release rate and magnesium stearate as an inert dispersing carrier to decrease the interfacial tension between lipophilic and hydrophilic phase.
Results: Prepared microcapsules were evaluated for the particle size, percentage yield, drug entrapment efficiency, flow property, and in vitro drug 
release for 12 hrs. Results indicated that the percentage yield, mean particle size, drug entrapment efficiency, and the micrometric properties of 
the microcapsules were influenced by various drug:polymer ratio. The release rate of microcapsules could be controlled as desired by adjusting the 
combination ratio of dispersing agents to retarding agents.
Conclusion: Perindopril microcapsules can be successfully designed to develop sustained drug delivery that reduces the dosing frequency and their 
by one can increase the patient compliance.
Keywords: Perindopril, Microencapsules, Solvent evaporation.
INTRODUCTION
Conventional oral dosage forms provide specific drug concentration in 
systemic circulation without offering any control over drug delivery and 
also cause great fluctuations in plasma levels. In case of conventional 
therapy, drug administered not only interact with targeted cells but 
also with normal healthy cells which often results in toxic effects, 
and this therapy also includes frequent administration of therapeutic 
agent which reduces patient compliance. The therapy also involves 
administration of high concentration of therapeutic agent to maintain 
its effect [1,2]. Research is gaining much attention is “controlled 
drug delivery” because of their more precise, reduced toxicity, and 
enhanced efficacy [3]. Various approaches in delivering a therapeutic 
substance to the target site in a sustained or controlled release fashion. 
In this regard, novel drug delivery systems have many benefits which 
include improved therapy by increasing the efficacy and duration of 
drug activity, increased patient compliance through decreased dosing 
frequency and convenient routes of administration and improved site 
specific delivery to reduce unwanted adverse effects [4,5].
The most exciting opportunities in CDDS lies in the area of responsive 
delivery systems, with which it will be possible to deliver drugs through 
implantable devices in response to a measured blood level or to deliver 
a drug precisely to a targeted site. Much of the developments of novel 
materials in controlled drug delivery are focusing on the preparation 
and use of the responsive polymers with specifically defined 
macroscopic and microscopic structural and chemical features. One 
such approach is using polymeric microcapsules as carriers for drug. 
Microencapsulation for oral use has been employed to control the drug 
release, and to reduce or eliminate gastrointestinal tract irritation. In 
addition, multi particulate delivery systems spread out more uniformly 
in the gastrointestinal tract. This result in more reproducible drug 
absorption and reduces local irritation when compared to single unit 
dosage forms.
Perindopril belongs to a class of medicines called angiotensin 
converting enzyme inhibitors, or ACE inhibitors. Since the drug is 
preferentially absorbed in the proximal small intestine (narrow 
absorption window), the drug displays oral bioavailability problems 
in conventional dosage forms. An elegant and simple way to improve 
drug absorption and release the drug in controlled manners is to 
hold the drug delivery system above the absorption window. As oral 
administration of perindopril results in peak plasma concentrations 
that occur at approximately 1 hr, half-life is 1.2 hrs. The absolute oral 
bioavailability of perindopril is about 75%. Following absorption, 
approximately 30-50% of systemically available. Perindopril doses of 
4-16 mg administered once daily are more effective than placebo in the 
treatment of mild-to-moderate hypertension [6,7].
The solvent evaporation method of microencapsulation involves the 
use of emulsification of a solution containing polymer and drug with an 
additional medium in which the drug and polymer cannot dissolve [8].
The aim of this work was to develop microcapsules of perindopril by 
solvent evaporation technique. Perindopril is water-soluble drug, we 
can control or delay the release rate of drug using microencapsulation. 
This may also decrease the toxic side effects by preventing the high 
initial concentration in the blood. Due to physicochemical properties 
and short half-life, it is a good candidate for microencapsulation.
METHODS
Perindopril was obtained as a gift sample from the Glenmark Pvt. 
Ltd., Goa, India. Copolymers (Eudragit® L-100 and S-100) and ethyl 
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cellulose were supplied as gift sample by Yarrow Chem. India Ltd., 
heavy liquid paraffin, was obtained from Nice Chemicals, Kochi, 
Kerala, India. Acetone was supplied by Labort Fine Chem, Surat, 
India. n-Hexane was supplied by Merck Specialties, Mumbai, India. 
Magnesium stearate was obtained from National Chemicals, Gujarat, 
India. All other chemicals and reagent used in this study were of 
analytical grade (Table 1).
Method of preparation [9]
Perindopril microspheres were prepared by solvent evaporation 
method using different quantities of Eudragit L100 and ethyl cellulose 
polymers. Approximately, 0.5, 1.0, and 1.5 g were accurately weighed 
and dissolved in 13.5 ml of acetone with stirring. A 500 mg quantity 
of drug and 50 mg of magnesium stearate were then dispersed in the 
polymer solution. The resultant milky white dispersion was poured into 
a vessel containing a mixture of 135 ml of liquid paraffin and 15 ml of 
n-hexane and stirred for 5 hrs using a homogenizer fitted with a four-
blade “butterfly” propeller. Stirring was continued for 3 hrs at 1000 rpm 
or until the acetone was completely evaporated. Following removal 
of acetone, the resultant microcapsules were harvested by vacuum 
filtration after which they were washed 4 times with 25 ml of n-hexane 




The general appearance and elegance of microcapsule were identified 
visually, which include size, shape, color, presence or absence of an 
odor, taste, and surface texture.
Percentage yield
The measured weight was divided by total amount of all nonvolatile 
components which were used for the preparation of microcapsule.
Percentage yield (%) = (Weight of microcapsules/Total weight of 
excipient and drug) × 100
Drug entrapment efficiency
The amount of perindopril present in the microcapsules is determined 
by extracting into acid buffer. Microcapsules are crushed and powdered 
using a mortar and pestle and accurately weighed amount of this 
powder is extracted into 100 ml of acid buffer (0.1 M hydrochloric acid) 
by stirring at 1000 rpm 2 hrs. The solution is filtered; suitable dilutions 
are made and absorbance was measured at 212 nm using ultraviolet 
(UV) spectrophotometer.
Drug entrapment efficiency (%) = Experimental drug content/
Theoretical drug content ×100
Micrometric properties [9]
Particle size
Determination of average particle size of perindopril microencapsules 
was carried out by the optical microscopy method. A minute quantity 
of microcapsules dispersed in glycerin and then spread on clean glass 
slide and average size of 100 microcapsules were determined in each 
batch.
Angle of repose
Determination of angle of repose perindopril microencapsules was 
carried out by employing fixed funnel method:
Angle of repose, θ=tan−1 (h/r)
Where, θ=Angle of repose,
h=Height of the pile,
r=Radius of the base of the pile.
Scanning electron microscopy (SEM) [9]
The samples for SEM analysis were prepared by following method. The 
shape and surface morphology of microcapsules were studied using 
SEM. Microcapsules were mounted directly onto the SEM sample stub 
using double-sided sticking tape and coated with gold film (thickness 
200 nm) under reduced pressure. The microcapsules were viewed at an 
accelerating voltage of 10 KV.
Drug release study [10]
In vitro release study: In vitro dissolution profile of each formulation 
was determined by employing rotating basket apparatus (Apparatus 
I) method (900 ml of 0.1 N HCl, 100 rpm, 37±0.5°C). Microcapsules 
equivalent to 100 mg of perindopril was loaded into the dissolution 
apparatus. Aliquot of 5 ml was withdrawn from the dissolution medium 
at suitable time intervals; sink conditions are maintained to keep the 
total volume constant. The dug release at different time intervals was 
measured using a double beam UV spectrophotometer at 212 nm. 
Results of in vitro drug release studies obtained from absorbance data 
were tabulated and shown graphically as cumulative % drug released 
versus time. The study was conducted in triplicate.
Stability study [11,12]
Stability testing was carried out to investigate the degradation of drug 
from microcapsule during storage condition. Best two (F3, F4) of the 
optimized perindopril microcapsule formulation sealed in glass vial and 
stored in accelerated condition (400±20°C/75%±5% RH) for 6 months. 
Protection from effect of change in the relative humidity was provided 
by keeping the formulation in the stability chamber. Samples from each 
batch were withdrawn after definite time intervals, drug entrapment 
efficiency, and drug release were analyzed.
RESULTS
Formulation characteristics
Perindopril microencapsules were prepared by solvent evaporation 
method using two different polymers Eudragit L100 and ethyl 
cellulose. The sustained release polymers Eudragit L100 and ethyl 
cellulose were employed to bind the inert solid dispersing carrier into 
microsphere and control the drug release rate. The popular method 
for the encapsulation of drugs within water-insoluble polymers is the 
emulsion solvent evaporation method. This technique offers several 
advantage and is preferable to other preparation methods such as 
spray drying, sonication, and homogenization because it requires only 
mild conditions such as ambient temperature and constant stirring. 
The use of magnesium stearate as a dispersion agent decreased the 
interfacial tension between the lipophilic and hydrophilic phases of the 
emulsion and further simplified the formation of microcapsules. As the 
solvent evaporated, the viscosity of the individual droplets increased, 
Table 1: Formulation of microcapsules
Formulation code Drug (mg) Eudragit L100 (mg) Ethyl cellulose (mg) Magnesium stearate (mg) Acetone (ml)
F1 (1:1) 500 500 - 50 13.5
F2 (1:2) 500 1000 - 50 13.5
F3 (1:3) 500 1500 - 50 13.5
F4 (1:1) 500 - 500 50 13.5
F5 (1:2) 500 - 1000 50 13.5
F6 (1:3) 500 - 1500 50 13.5
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and highly viscous droplets were observed to coalesce at a faster rate 
than they could be separated. Magnesium stearate formed a thin film 
around the droplets and thereby reduced the extent of coalescence, 
before hardening of the capsules, on collision of droplets. The resultant 
microcapsules were free-flowing, and the use of magnesium stearate 
was deemed effective. Liquid paraffin was selected as a bulk or outer 
phase since drug and polymers are only very slightly soluble in liquid 
paraffin. Acetone has a dielectric constant of 20.7 and was therefore 
chosen as the dispersed or inner phase since solvents with dielectric 
constants between 10 and 40 show poor miscibility with liquid 
paraffin. Microcapsules that were formulated with low concentrations 
of Eudragit L100 and ethyl cellulose were irregular, nonspherical, soft, 
and had poor flow ability, therefore, they were not considered suitable 
for analysis. During processing, it was observed that stirrer speeds of 
<500 rpm were not sufficient to produce microcapsules, and a huge 
coalesce was obtained. This is due in part to inadequate agitation of 
the media to disperse the inner phase in discreet droplets within the 
bulk phase. At stirring speeds above 1000 rpm, the turbulence caused 
frothing and adhesion of the micro particles to the container walls and 
propeller blade surfaces, resulting in high shears, and smaller size of 
dispersed droplets. Spherical microspheres were obtained at a stirring 
rate of 1000 rpm; therefore, this speed was used during manufacture 
of all microcapsules. Many formulations were prepared, to investigate 
the effect of increasing amount of the polymer and dispersing agent on 
the microcapsule formulation. The drug polymer and drug dispersing 
agent ratio was altered while the amounts of solvent and stirring rate 
were kept constant.
Yield of microcapsules
From Table 2, it was observed that F1 showed the greatest percentage 
yield that is 76.40%. The other formulations showed comparatively less 
percentage yield.
Incorporation efficiency
The values of drug entrapment efficiency are shown in Table 2. As the 
polymer concentration was increased, the percentage drug entrapment 
efficiency was increased due to increase in the viscosity of the solution. 
This can be attributed to the permeation characteristics of each 
polymer used.
Micromeritic properties
The arithmetic mean particle size of the formulations was determined 
by the optical microscope fitted with an ocular micrometer and stage 
micrometer. The average mean particle sizes of six formulations 
were 265.50±0.69, 312.82±0.90, 365.60±0.67, 309.10±0.15, 
351.35±0.78, and 323.08±0.50, respectively. The mean particle size 
of the microcapsules significantly increased with increase in polymer 
concentration due to high viscosity of medium at a higher polymer 
concentration resulting in enhanced interfacial tension and diminished 
shearing efficiency.
Angle of repose of microcapsules was in range of 18° 80”±3.89 to 26° 
56”±1.17 (Table 3). These values indicate an overall good free flowing 
nature of microcapsules of all batches.
SEM
SEM of the formulation F3 and F4 was carried out. It was observed 
that the microcapsules were spherical in shape with smooth surface. 
Photomicrograph of the formulation F3 and F4 also revealed that 
the microcapsules were spherical in shape (Fig. 1). In F1, the drug to 
polymer ratio was 1:1. So proper coating was not observed. When the 
concentration of polymer was increased as in F3 (1:3), proper coating 
was done and prepared microcapsules had the spherical shape and 
smooth surface.
In-vitro release studies
The ultimate aim of this work was to develop sustained release drug 
delivery system of perindopril. The drug release from batches F1 to 
F6 indicated that as the polymer concentration increased the release 
rate decreased (Fig. 3). The release rate of perindopril from the 
microcapsules can be modulated with adjusting the drug to polymer 
ratio. As the concentration of polymer was increased, the amount 
of drug release was decreased. Hence, polymer acts like a retarding 
material. It is important to note that the dissolution behavior of granules 
and powders is greatly influenced by their wettability, surface area, and 
particle size distribution. The formulation F3 shows the maximum 
cumulative drug release within 12 hrs. The overall cumulative % 
release for F1, F2, F3, F4, F5, and F6 were found to be 84.20±0.66, 
74.43±1.69, 94.58±0.79, 89.60±1.92, 81.82±0.53, and 78.87±1.30 at 
the end of 12th hr.
Fig. 1: Scanning electron microscopy F3, F4
Table 2: Yield of microcapsules








Table 3: Micromeritic properties
Formulation code Mean particle size (µm) Angle of repose
F1 265.50±0.69 18° 80”±3.89
F2 312.82±0.90 21° 39”±2.78
F3 365.60±0.67 22° 44”±1.93
F4 309.10±0.15 25° 64” ±0.68
F5 351.35±0.78 22° 76”±3.39
F6 323.08±0.50 26° 56”±1.17
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Fig. 3: Microscopic evaluation of F4
CONCLUSION
This study was attempted to develop microcapsules of perindopril for 
the treatment of blood pressure. Sustained release microcapsules of 
perindopril were developed using combination of release retardant 
polymers, Eudragit L100, and ethyl cellulose by solvent evaporation 
method. Six formulations were prepared using two different polymers. 
All the formulations were subjected to drug entrapment studies, 
particle size determination, and in vitro drug release studies. The 
microcapsules were satisfactory considering their percentage yield, 
size, and drug entrapment. On the basis of release studies, it was 
indicated that the polymers Eudragit L100 and ethyl cellulose retards 
the release of perindopril from microcapsules. The preparation process 
was simple, reproducible, and the resultant microcapsules had the 
desired micrometric properties. Hence, this study revealed that the 
microcapsules of perindopril prepared by solvent evaporation method 
could sustain the drug release, and thus, it is a relevant alternative of 
conventional dosage forms.
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